Skip to main content
SpringerLink
Log in
Book cover

Drug Adherence in Hypertension and Cardiovascular Protection pp 297–314Cite as

Global Clinical Consequences of Poor Adherence

  • Chapter
  • First Online:

  • 717 Accesses

Part of the book series: Updates in Hypertension and Cardiovascular Protection ((UHCP))

Abstract

The chapter on healthcare consequences of non-adherence initially presents the thematic of global prevalence and healthcare costs of uncontrolled hypertension, followed by the clinical consequences of non-adherence to antihypertensive drugs. Drug adherence is a complex phenomenon and may be influenced by many factors, one of which is the coexistence of other chronic diseases. Thus, a discussion exposing the relationship of drug adherence with the presence of associated morbidities is presented. Subsequently, an overview of the risk prediction and the population impact of implementing guidelines and interventions on drug adherence are depicted. The discussion is further followed by the technology advances and healthcare reform efforts creating an opportunities to reshape the current system where evidence generated from observational studies could contribute to better meet stakeholder needs. Several considerations of the clinical consequences of healthcare professional and system on drug adherence are introduced. Finally, the last section considers the clinical consequences of implementing patient-centered approaches and personalized evaluations of adherence to antihypertensive drugs, as well as the clinical consequences of changes to healthcare professional- and policy-related factors on adherence.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. World Health Organization. A global brief on hypertension. Silent killer, global public health crisis. 2016.

    Google Scholar 

  2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37–55.

    Article  Google Scholar 

  3. World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization; 2009. p. 1–62.

    Google Scholar 

  4. Heidenreich PA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.

    Article  PubMed  Google Scholar 

  5. Gaziano TA, Bitton A, Anand S, Weinstein MC, International Society of Hypertension. The global cost of nonoptimal blood pressure. J Hypertens. 2009;27:1472–7.

    Article  PubMed  CAS  Google Scholar 

  6. Townsend N, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37:3232–45.

    Article  PubMed  Google Scholar 

  7. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.

    Google Scholar 

  8. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11–9.

    Article  PubMed  CAS  Google Scholar 

  9. Lewanczuk R. Innovations in primary care: implication for hypertension detection and treatment. Can J Cardiol. 2006;22:614–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Gee ME, et al. Antihypertensive medication use, adherence, stops, and starts in Canadians with hypertension. Can J Cardiol. 2012;28:383–9.

    Article  PubMed  Google Scholar 

  11. Wolf-Maier K, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:2363–9.

    Article  PubMed  Google Scholar 

  12. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043–50.

    Article  PubMed  CAS  Google Scholar 

  13. Egan BM, Zhao Y. Different definitions of prevalent hypertension impact: the clinical epidemiology of hypertension and attainment of Healthy People goals. J Clin Hypertens (Greenwich). 2013;15:154–61.

    Article  Google Scholar 

  14. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:1046–58.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Resnick HE, Shorr RI, Kuller L, Franse L, Harris TB. Prevalence and clinical implications of American Diabetes Association-defined diabetes and other categories of glucose dysregulation in older adults: the health, aging and body composition study. J Clin Epidemiol. 2001;54:869–76.

    Article  PubMed  CAS  Google Scholar 

  16. Smith NL, et al. Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: the Cardiovascular Health Study. J Am Geriatr Soc. 2002;50:416–23.

    Article  PubMed  Google Scholar 

  17. de Rekeneire N, et al. Racial differences in glycemic control in a well-functioning older diabetic population: findings from the Health, Aging and Body Composition Study. Diabetes Care. 2003;26:1986–92.

    Article  PubMed  Google Scholar 

  18. Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc. 2007;55:1056–65.

    Article  PubMed  Google Scholar 

  19. Robinson JG, Booth B. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol. 2010;4:483–90.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Egan BM, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62:691–7.

    Article  PubMed  CAS  Google Scholar 

  21. Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006;27:1610–9.

    Article  PubMed  Google Scholar 

  22. Mennini FS, et al. Cost of poor adherence to anti-hypertensive therapy in five European countries. Eur J Health Econ. 2015;16:65–72.

    Article  PubMed  CAS  Google Scholar 

  23. Lim SS, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Breekveldt-Postma NS, et al. Effect of persistent use of antihypertensives on blood pressure goal attainment. Curr Med Res Opin. 2008;24:1025–31.

    Article  PubMed  Google Scholar 

  25. LaFleur J, Oderda GM. Methods to measure patient compliance with medication regimens. J Pain Palliat Care Pharmacother. 2004;18:81–7.

    Article  PubMed  Google Scholar 

  26. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36:1331–6.

    Article  PubMed  Google Scholar 

  27. Shin S, et al. Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients. Hypertens Res. 2013;36:1000–5.

    Article  PubMed  Google Scholar 

  28. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69–75.

    Article  PubMed  CAS  Google Scholar 

  29. Krousel-Wood MA, Muntner P, He J, Whelton PK. Primary prevention of essential hypertension. Med Clin North Am. 2004;88:223–38.

    Article  PubMed  Google Scholar 

  30. Chobanian AV, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.

    Article  PubMed  CAS  Google Scholar 

  31. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10:348–54.

    Article  Google Scholar 

  32. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794–811.

    Article  PubMed  Google Scholar 

  33. Lawes CM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–8.

    Article  PubMed  Google Scholar 

  34. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Blood Pressure Lowering Treatment Trialists’ Collaboration, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121–3.

    PubMed Central  Google Scholar 

  36. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess. 2003;7:1–94.

    Article  PubMed  CAS  Google Scholar 

  37. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.

    Article  PubMed  CAS  Google Scholar 

  38. Burke TA, et al. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens. 2006;24:1193–200.

    Article  PubMed  Google Scholar 

  39. Benner JS, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455–61.

    Article  PubMed  Google Scholar 

  40. Perreault S, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol. 2005;61:667–74.

    Article  PubMed  Google Scholar 

  41. Perreault S, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother. 2005;39:1401–8.

    Article  PubMed  CAS  Google Scholar 

  42. Perreault S, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol. 2005;59:564–73.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Simard P, et al. Persistence and adherence to oral antidiabetics: a population-based cohort study. Acta Diabetol. 2015;52:547–56.

    Article  PubMed  CAS  Google Scholar 

  44. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114–7.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Mazzaglia G, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23:2093–100.

    Article  CAS  PubMed  Google Scholar 

  46. Sung SK, et al. First-year treatment adherence among outpatients initiating antihypertensive medication in Korea: results of a retrospective claims review. Clin Ther. 2009;31:1309–20.

    Article  PubMed  Google Scholar 

  47. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521–30.

    Article  PubMed  Google Scholar 

  48. Liu L, et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res. 2009;32:1032–40.

    Article  PubMed  Google Scholar 

  49. Ho PM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155:772–9.

    Article  PubMed  Google Scholar 

  50. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62:76–87.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Dragomir A, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48:418–25.

    Article  PubMed  Google Scholar 

  52. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010;16:568–76.

    PubMed  Google Scholar 

  53. Wu PH, et al. Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan. Am J Hypertens. 2010;23:155–60.

    Article  PubMed  Google Scholar 

  54. Mazzaglia G, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598–605.

    Article  PubMed  CAS  Google Scholar 

  55. Perreault S, et al. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol. 2010;69:74–84.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Kettani FZ, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009;40:213–20.

    Article  PubMed  Google Scholar 

  57. Perreault S, et al. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med. 2009;266:207–18.

    Article  PubMed  CAS  Google Scholar 

  58. Perreault S, et al. Adherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes. Neurology. 2012;79:2037–43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Wong MC, et al. Drug adherence and the incidence of coronary heart disease- and stroke-specific mortality among 218,047 patients newly prescribed an antihypertensive medication: a five-year cohort study. Int J Cardiol. 2013;168:928–33.

    Article  PubMed  Google Scholar 

  60. Kim S, et al. Medication adherence and the risk of cardiovascular mortality and hospitalization among patients with newly prescribed antihypertensive medications. Hypertension. 2016;67:506–12.

    PubMed  CAS  Google Scholar 

  61. Schafer HH, Scheunert U. Costs of current antihypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care. Swiss Med Wkly. 2013;143:w13854.

    PubMed  Google Scholar 

  62. Roy L, et al. Adherence to antihypertensive agents improves risk reduction of end-stage renal disease. Kidney Int. 2013;84:570–7.

    Article  PubMed  CAS  Google Scholar 

  63. van der Laan MJ, Polley EC, Hubbard AE. Super learner. Stat Appl Genet Mol Biol. 2007;6:Article25.

    Google Scholar 

  64. Obermeyer Z, Emanuel EJ. Predicting the future—big data, machine learning, and clinical medicine. N Engl J Med. 2016;375:1216–9.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Kennedy EH, Ma Z, McHugh MD, Small DS. Nonparametric methods for doubly robust estimation of continuous treatment effects. J R Stat Soc Ser B. 2017;79(4):1229–45.

    Article  Google Scholar 

  66. Krousel-Wood M, et al. Association of depression with antihypertensive medication adherence in older adults: cross-sectional and longitudinal findings from CoSMO. Ann Behav Med. 2010;40:248–57.

    Article  PubMed  Google Scholar 

  67. ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31:1925–38.

    Article  CAS  Google Scholar 

  68. Ghembaza MA, Senoussaoui Y, Tani MK, Meguenni K. Impact of patient knowledge of hypertension complications on adherence to antihypertensive therapy. Curr Hypertens Rev. 2014;10:41–8.

    Article  PubMed  CAS  Google Scholar 

  69. An J, Nichol MB. Multiple medication adherence and its effect on clinical outcomes among patients with comorbid type 2 diabetes and hypertension. Med Care. 2013;51:879–87.

    Article  PubMed  Google Scholar 

  70. Carretero OA, Oparil S. Essential hypertension: part II: treatment. Circulation. 2000;101:446–53.

    Article  PubMed  CAS  Google Scholar 

  71. Scalco AZ, Scalco MZ, Azul JB, Lotufo Neto F. Hypertension and depression. Clinics (Sao Paulo). 2005;60:241–50.

    Article  Google Scholar 

  72. Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed. 2007;9:58.

    PubMed  PubMed Central  Google Scholar 

  73. Jamous RM, et al. Adherence and satisfaction with oral hypoglycemic medications: a pilot study in Palestine. Int J Clin Pharm. 2011;33:942–8.

    Article  PubMed  Google Scholar 

  74. Ahmad NS, Ramli A, Islahudin F, Paraidathathu T. Medication adherence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia. Patient Prefer Adherence. 2013;7:525–30.

    PubMed  PubMed Central  Google Scholar 

  75. Simard P, et al. Impact of adherence to oral antidiabetics on all-cause mortality: a population based study. Value Health. 2015;18:A611.

    Article  CAS  Google Scholar 

  76. Dunlay SM, Eveleth JM, Shah ND, McNallan SM, Roger VL. Medication adherence among community-dwelling patients with heart failure. Mayo Clin Proc. 2011;86:273–81.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Wu JR, Lennie TA, Dekker RL, Biddle MJ, Moser DK. Medication adherence, depressive symptoms, and cardiac event-free survival in patients with heart failure. J Card Fail. 2013;19:317–24.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Perreault S, et al. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. Pharmacoepidemiol Drug Saf. 2017;26:81–90.

    Article  PubMed  CAS  Google Scholar 

  79. Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12:20.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Sweileh WM, et al. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav. 2011;21:301–5.

    Article  PubMed  Google Scholar 

  81. De las Cuevas C, Penate W, Sanz EJ. Risk factors for non-adherence to antidepressant treatment in patients with mood disorders. Eur J Clin Pharmacol. 2014;70:89–98.

    Article  CAS  Google Scholar 

  82. Cooper DC, et al. Antidepressant adherence and risk of coronary artery disease hospitalizations in older and younger adults with depression. J Am Geriatr Soc. 2014;62:1238–45.

    Article  PubMed  Google Scholar 

  83. Hashmi SK, et al. Factors associated with adherence to anti-hypertensive treatment in Pakistan. PLoS One. 2007;2:e280.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Li WW, Kuo CT, Hwang SL, Hsu HT. Factors related to medication non-adherence for patients with hypertension in Taiwan. J Clin Nurs. 2012;21:1816–24.

    Article  PubMed  Google Scholar 

  85. Holt E, et al. Sex differences in barriers to antihypertensive medication adherence: findings from the cohort study of medication adherence among older adults. J Am Geriatr Soc. 2013;61:558–64.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Wang W, Lau Y, Loo A, Chow A, Thompson DR. Medication adherence and its associated factors among Chinese community-dwelling older adults with hypertension. Heart Lung. 2014;43:278–83.

    Article  PubMed  Google Scholar 

  87. Agh T, Inotai A, Meszaros A. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 2011;82:328–34.

    Article  PubMed  Google Scholar 

  88. Blais L, Forget A, Ramachandran S. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin Ther. 2010;32:1320–8.

    Article  PubMed  Google Scholar 

  89. Jansa M, et al. Multidimensional analysis of treatment adherence in patients with multiple chronic conditions. A cross-sectional study in a tertiary hospital. Patient Educ Couns. 2010;81:161–8.

    Article  PubMed  Google Scholar 

  90. Tsai KT, et al. Medication adherence among geriatric outpatients prescribed multiple medications. Am J Geriatr Pharmacother. 2012;10:61–8.

    Article  PubMed  Google Scholar 

  91. Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004;351:2870–4.

    Article  PubMed  CAS  Google Scholar 

  92. Qvarnstrom M, et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol. 2013;69:1955–64.

    Article  CAS  PubMed  Google Scholar 

  93. Hasford J, Schroder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol. 2007;63:1055–61.

    Article  PubMed  Google Scholar 

  94. Morris AB, et al. Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy. 2006;26:483–92.

    Article  PubMed  Google Scholar 

  95. Chapman RH, Petrilla AA, Benner JS, Schwartz JS, Tang SS. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging. 2008;25:885–92.

    Article  PubMed  Google Scholar 

  96. Wong MC, et al. The association between multimorbidity and poor adherence with cardiovascular medications. Int J Cardiol. 2014;177:477–82.

    Article  PubMed  Google Scholar 

  97. Wong MC, et al. Factors associated with multimorbidity and its link with poor blood pressure control among 223,286 hypertensive patients. Int J Cardiol. 2014;177:202–8.

    Article  PubMed  Google Scholar 

  98. Calderon-Larranaga A, et al. Non-adherence to antihypertensive medication: the role of mental and physical comorbidity. Int J Cardiol. 2016;207:310–6.

    Article  PubMed  Google Scholar 

  99. Saadat Z, et al. Adherence to antihypertensives in patients with comorbid condition. Nephrourol Mon. 2015;7:e29863.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Stewart M, Fortin M, Britt HC, Harrison CM, Maddocks HL. Comparisons of multi-morbidity in family practice—issues and biases. Fam Pract. 2013;30:473–80.

    Article  PubMed  PubMed Central  Google Scholar 

  101. James PA, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.

    Article  PubMed  CAS  Google Scholar 

  102. Navar-Boggan AM, Pencina MJ, Williams K, Sniderman AD, Peterson ED. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA. 2014;311:1424–9.

    Article  PubMed  CAS  Google Scholar 

  103. Anderson JL, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329–45.

    Article  PubMed  Google Scholar 

  104. Moran AE, et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015;372:447–55.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  105. Abraham JM. Using microsimulation models to inform U.S. health policy making. Health Serv Res. 2013;48:686–95.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Fontil V, et al. Simulating strategies for improving control of hypertension among patients with usual source of Care in the United States: the blood pressure control model. J Gen Intern Med. 2015;30:1147–55.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Jha AK. Learning from the past to improve VA health care. JAMA. 2016;315:560–1.

    Article  PubMed  CAS  Google Scholar 

  108. Rumsfeld JS, Joynt KE, Maddox TM. Big data analytics to improve cardiovascular care: promise and challenges. Nat Rev Cardiol. 2016;13:350–9.

    Article  PubMed  CAS  Google Scholar 

  109. Hussey PS, Eibner C, Ridgely MS, McGlynn EA. Controlling U.S. health care spending—separating promising from unpromising approaches. N Engl J Med. 2009;361:2109–11.

    Article  PubMed  CAS  Google Scholar 

  110. Fields D, Leshen E, Patel K. Analysis & commentary. Driving quality gains and cost savings through adoption of medical homes. Health Aff (Millwood). 2010;29:819–26.

    Article  Google Scholar 

  111. Rosenthal MB, et al. Will the patient-centered medical home improve efficiency and reduce costs of care? A measurement and research agenda. Med Care Res Rev. 2010;67:476–84.

    Article  PubMed  Google Scholar 

  112. Peikes D, Zutshi A, Genevro JL, Parchman ML, Meyers DS. Early evaluations of the medical home: building on a promising start. Am J Manag Care. 2012;18:105–16.

    PubMed  Google Scholar 

  113. Sidorov JE. The patient-centered medical home for chronic illness: is it ready for prime time? Health Aff (Millwood). 2008;27:1231–4.

    Article  Google Scholar 

  114. Beadles CA, et al. Do medical homes increase medication adherence for persons with multiple chronic conditions? Med Care. 2015;53:168–76.

    Article  PubMed  Google Scholar 

  115. https://secure.cihi.ca/free_products/HCIC_2011_seniors_report_en.pdf. 2011.

  116. Committee on Quality of Health Care in America, Institute of Medicine. To err is human: building a safer health system. Washington, DC: National Academies Press; 2000.

    Google Scholar 

  117. Baker GR, et al. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. CMAJ. 2004;170:1678–86.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Center for Drug Evaluation And Research (CDER), FDA. http://www.Fda.Gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm110632.Htm#adrs: Prevalence and incidence.

  119. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652–8.

    Article  PubMed  CAS  Google Scholar 

  120. Turgeon J, Michaud V. Clinical decision support systems: great promises for better management of patients’ drug therapy. Expert Opin Drug Metab Toxicol. 2016;12:993–5.

    Article  PubMed  Google Scholar 

  121. Zakrzewski-Jakubiak H, et al. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software. Am J Geriatr Pharmacother. 2011;9:461–70.

    Article  PubMed  CAS  Google Scholar 

  122. Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013;47:324–32.

    Article  PubMed  CAS  Google Scholar 

  123. Wang L. Physician-related barriers to hypertension management. Med Princ Pract. 2004;13:282–5.

    Article  PubMed  Google Scholar 

  124. Mehta SS, Wilcox CS, Schulman KA. Treatment of hypertension in patients with comorbidities: results from the study of hypertensive prescribing practices (SHyPP). Am J Hypertens. 1999;12:333–40.

    PubMed  CAS  Google Scholar 

  125. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med. 2000;160:2281–6.

    Article  PubMed  CAS  Google Scholar 

  126. Milchak JL, Carter BL, James PA, Ardery G. Measuring adherence to practice guidelines for the management of hypertension: an evaluation of the literature. Hypertension. 2004;44:602–8.

    Article  PubMed  CAS  Google Scholar 

  127. McAlister FA, O’Connor AM, Wells G, Grover SA, Laupacis A. When should hypertension be treated? The different perspectives of Canadian family physicians and patients. CMAJ. 2000;163:403–8.

    PubMed  PubMed Central  CAS  Google Scholar 

  128. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479–86.

    Article  PubMed  CAS  Google Scholar 

  129. Ragot S, Beneteau M, Guillou-Bonnici F, Herpin D. Prevalence and management of hypertensive patients in clinical practice: cross-sectional registry in five countries outside the European Union. Blood Press. 2016;25:104–16.

    Article  PubMed  Google Scholar 

  130. EUGenMed Cardiovascular Clinical Study Group, et al. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016;37:24–34.

    Article  CAS  Google Scholar 

  131. Al-Ansary LA, et al. A systematic review of recent clinical practice guidelines on the diagnosis, assessment and management of hypertension. PLoS One. 2013;8:e53744.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  132. Cai L, Liu A, Zhang L, Li S, Wang P. Prevalence, awareness, treatment, and control of hypertension among adults in Beijing, China. Clin Exp Hypertens. 2012;34:45–52.

    Article  PubMed  CAS  Google Scholar 

  133. Whelton PK, He J, Muntner P. Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. J Hum Hypertens. 2004;18:545–51.

    Article  PubMed  CAS  Google Scholar 

  134. Alsuwaida A, Alghonaim M. Gender disparities in the awareness and control of hypertension. Clin Exp Hypertens. 2011;33:354–7.

    Article  PubMed  Google Scholar 

  135. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007;167:141–7.

    Article  PubMed  Google Scholar 

  136. Fervers B, et al. Predictors of high quality clinical practice guidelines: examples in oncology. Int J Qual Health Care. 2005;17:123–32.

    Article  PubMed  Google Scholar 

  137. Watine J, et al. Conflict between guideline methodologic quality and recommendation validity: a potential problem for practitioners. Clin Chem. 2006;52:65–72.

    Article  PubMed  CAS  Google Scholar 

  138. Nagy E, et al. Do guidelines for the diagnosis and monitoring of diabetes mellitus fulfill the criteria of evidence-based guideline development? Clin Chem. 2008;54:1872–82.

    Article  PubMed  CAS  Google Scholar 

  139. Tai-Seale M, McGuire TG, Zhang W. Time allocation in primary care office visits. Health Serv Res. 2007;42:1871–94.

    Article  PubMed  PubMed Central  Google Scholar 

  140. Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener JL. Primary care: is there enough time for prevention? Am J Public Health. 2003;93:635–41.

    Article  PubMed  PubMed Central  Google Scholar 

  141. Maciosek MV, et al. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med. 2006;31:52–61.

    Article  PubMed  Google Scholar 

  142. Ostbye T, et al. Is there time for management of patients with chronic diseases in primary care? Ann Fam Med. 2005;3:209–14.

    Article  PubMed  PubMed Central  Google Scholar 

  143. Flocke SA, Frank SH, Wenger DA. Addressing multiple problems in the family practice office visit. J Fam Pract. 2001;50:211–6.

    PubMed  CAS  Google Scholar 

  144. Fiscella K, Epstein RM. So much to do, so little time: care for the socially disadvantaged and the 15-minute visit. Arch Intern Med. 2008;168:1843–52.

    Article  PubMed  PubMed Central  Google Scholar 

  145. Pimlott N. Preventive care: so many recommendations, so little time. CMAJ. 2005;173:1345–6.

    Article  PubMed  PubMed Central  Google Scholar 

  146. Tarn DM, et al. How much time does it take to prescribe a new medication? Patient Educ Couns. 2008;72:311–9.

    Article  PubMed  PubMed Central  Google Scholar 

  147. Hadley J, Mitchell JM, Sulmasy DP, Bloche MG. Perceived financial incentives, HMO market penetration, and physicians’ practice styles and satisfaction. Health Serv Res. 1999;34:307–21.

    PubMed  PubMed Central  CAS  Google Scholar 

  148. Nutting PA, Rost K, Smith J, Werner JJ, Elliot C. Competing demands from physical problems: effect on initiating and completing depression care over 6 months. Arch Fam Med. 2000;9:1059–64.

    Article  PubMed  CAS  Google Scholar 

  149. Linzer M, et al. Managed care, time pressure, and physician job satisfaction: results from the physician worklife study. J Gen Intern Med. 2000;15:441–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  150. Mechanic D. Physician discontent: challenges and opportunities. JAMA. 2003;290:941–6.

    Article  PubMed  Google Scholar 

  151. Nutting PA, et al. Competing demands in the office visit: what influences mammography recommendations? J Am Board Fam Pract. 2001;14:352–61.

    PubMed  CAS  Google Scholar 

  152. Taksler GB, Keshner M, Fagerlin A, Hajizadeh N, Braithwaite RS. Personalized estimates of benefit from preventive care guidelines: a proof of concept. Ann Intern Med. 2013;159:161–8.

    Article  PubMed  Google Scholar 

  153. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care. 2006;29:725–31.

    Article  PubMed  Google Scholar 

  154. O’Connor PJ. Setting evidence-based priorities for diabetes care improvement. Int J Qual Health Care. 2003;15:283–5.

    Article  PubMed  Google Scholar 

  155. Braithwaite RS, Concato J, Chang CC, Roberts MS, Justice AC. A framework for tailoring clinical guidelines to comorbidity at the point of care. Arch Intern Med. 2007;167:2361–5.

    Article  PubMed  PubMed Central  Google Scholar 

  156. Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296:2336–42.

    Article  PubMed  CAS  Google Scholar 

  157. Melgarejo JD, et al. Prevalence, treatment, and control rates of conventional and ambulatory hypertension across 10 populations in 3 continents. Hypertension. 2017;70:50–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada

    Sylvie Perreault B.Pharm., Ph.D.

Authors
  1. Sylvie Perreault B.Pharm., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sylvie Perreault B.Pharm., Ph.D. .

Editor information

Editors and Affiliations

  1. Service of Nephrology and Hypertension, CHUV, University of Lausanne, Lausanne, Vaud, Switzerland

    Michel Burnier

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Perreault, S. (2018). Global Clinical Consequences of Poor Adherence. In: Burnier, M. (eds) Drug Adherence in Hypertension and Cardiovascular Protection. Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-319-76593-8_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-76593-8_22

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-76592-1

  • Online ISBN: 978-3-319-76593-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation